detorubicin and Leukemia

detorubicin has been researched along with Leukemia* in 2 studies

Other Studies

2 other study(ies) available for detorubicin and Leukemia

Article	Year
Anthracyclines in the treatment of acute nonlymphocytic leukemias. Cancer treatment reports, 1981, Volume: 65 Suppl 4 Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Heart Diseases; Humans; Leukemia; Middle Aged; Naphthacenes	1981
Experimental and clinical activity of a new anthracycline derivative: detorubicin (14-diethoxyacetoxydaunorubicin). Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1980, Volume: 74 This report concerns the experimental activity and the preliminary clinical results obtained with detorubicin, an anthracycline. Experimentally, in comparison with doxorubicin, detorubicin is less toxic, less immunodepressive, and less mutagenic, its experimental antitumor activity is equal or superior, and differences are found in pharmacokinetics. Its most interesting activities in clinical cancer therapy are found in non-Hodgkin lymphomas, in carcinomas, and in soft-tissue sarcomas. Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Mice; Mutagens; Neoplasms; Neoplasms, Experimental	1980

Article

Year

Anthracyclines in the treatment of acute nonlymphocytic leukemias.

Cancer treatment reports, 1981, Volume: 65 Suppl 4

Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Heart Diseases; Humans; Leukemia; Middle Aged; Naphthacenes

1981

Experimental and clinical activity of a new anthracycline derivative: detorubicin (14-diethoxyacetoxydaunorubicin).

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1980, Volume: 74

This report concerns the experimental activity and the preliminary clinical results obtained with detorubicin, an anthracycline. Experimentally, in comparison with doxorubicin, detorubicin is less toxic, less immunodepressive, and less mutagenic, its experimental antitumor activity is equal or superior, and differences are found in pharmacokinetics. Its most interesting activities in clinical cancer therapy are found in non-Hodgkin lymphomas, in carcinomas, and in soft-tissue sarcomas.

Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Mice; Mutagens; Neoplasms; Neoplasms, Experimental

1980